Deciphera Pharmaceuticals LLC (DCPH)

NASDAQ
35.42
+1.15(+3.36%)
After Hours
35.42
0.00(0.00%)
- Real-time Data
  • Volume:
    357,075
  • Bid/Ask:
    33.05/36.50
  • Day's Range:
    33.91 - 35.50

DCPH Overview

Prev. Close
34.27
Day's Range
33.91-35.5
Revenue
67.19M
Open
34.09
52 wk Range
31.77-68.4
EPS
-4.49
Volume
357,075
Market Cap
2.05B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
420,857
P/E Ratio
-
Beta
1.51
1-Year Change
-34.7%
Shares Outstanding
57,964,496
Next Earnings Date
Aug 10, 2021
What is your sentiment on Deciphera Pharmaceuticals LLC?
or
Market is currently closed. Voting is open during market hours.

Deciphera Pharmaceuticals LLC News

Deciphera Pharmaceuticals LLC Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyStrong BuyNeutralSell
Technical IndicatorsStrong BuyBuyStrong BuyBuyStrong Sell
SummaryStrong BuyStrong BuyStrong BuyNeutralStrong Sell

Deciphera Pharmaceuticals LLC Company Profile

Deciphera Pharmaceuticals LLC Company Profile

Employees
350

Deciphera Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing drugs to improve the lives of cancer patients. Its drug candidate includes DCC-2618, DCC-3014 and Rebastinib. Its proprietary kinase switch control inhibitor platform, inhibit the activation of kinases. DCC-2618, an orally administered kinase switch control inhibitor, for the treatment of gastrointestinal stromal tumors (GIST), advanced systemic mastocytosis (ASM), gliomas, including glioblastoma multiforme (GBM), and other solid tumors driven by pan-KIT or PDGFR alpha. DCC-3014 is an orally administered, potent and highly selective inhibitor of colony stimulating factor receptor 1 (CSF1R). Rebastinib is an orally administered, potent and selective inhibitor of the TIE2 immunokinase. Rebastinib binds potently into the switch pocket of TIE2, stabilizing the inhibitory switch and displacing the activation switch to block TIE2 signaling.

Read More
  • This stock gonna crash
    1
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.